LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users

Forensic Science International

Volumn 209, Issue 1-3, 2011, Pages 113-119

  Seldén, Tor ^a,d   Roman, Markus ^a   Druid, Henrik ^b,c   Kronstrand, Robert ^a,d  

^a National Board of Forensic Medicine   (Sweden)

^b DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Buprenorphine; DUID; LC MS MS; Whole blood

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; CANNABIS; COCAINE; DRUG METABOLITE; GLUCURONIDE; NORBUPRENORPHINE; OPIATE;

ACCURACY; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BLOOD STORAGE; CONTROLLED STUDY; DRIVING UNDER THE INFLUENCE OF DRUG; DRUG DEGRADATION; DRUG IDENTIFICATION; DRUG STABILITY; DRUG USE; FEMALE; FORENSIC IDENTIFICATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; PETTY DRUG OFFENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STORAGE TEMPERATURE; TANDEM MASS SPECTROMETRY;

EID: 79957602047     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.01.011     Document Type: Article

References (40)

1. Escher M., Daali Y., Chabert J., Hopfgartner G., Dayer P., Desmeules J. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin. Ther. 2007, 29:1620-1631.
2. Elkader A., Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 2005, 44:661-680.
3. Jagsch R., Gombas W., Schindler S.D., Eder H., Moody D.E., Fischer G. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients. Addict. Biol. 2005, 10:365-371.
4. McAleer S.D., Mills R.J., Polack T., Hussain T., Rolan P.E., Gibbs A.D., Mullins F.G., Hussein Z. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend. 2003, 72:75-83.
5. Mintzer M.Z., Correia C.J., Strain E.C. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend. 2004, 74:205-209.
6. Murphy C.M., Huestis M.A. Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-d-glucuronide and norbuprenorphine-3-beta-d-glucuronide in human plasma. J. Mass Spectrom. 2005, 40:70-74.
7. Oechsler S., Skopp G. Buprenorphine and major metabolites in blood specimens collected for drug analysis in law enforcement purposes. Forensic Sci. Int. 2010, 195:73-77.
8. Polettini A., Huestis M.A. Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Biomed. Sci. Appl. 2001, 754:447-459.
9. Kuhlman J.J., Levine B., Johnson R.E., Fudala P.J., Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction (Abingdon, England) 1998, 93:549-559.
10. Chawarski M.C., Schottenfeld R.S., O'Connor P.G., Pakes J. Plasma concentrations of buprenorphine 24 to 72hours after dosing. Drug Alcohol Depend. 1999, 55:157-163.
11. Bruce R.D., Altice F.L., Moody D.E., Lin S.N., Fang W.B., Sabo J.P., Wruck J.M., Piliero P.J., Conner C., Andrews L., Friedland G.H. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend. 2009, 105:234-239.
12. Aalto M., Halme J., Visapaa J.P., Salaspuro M. Buprenorphine misuse in Finland. Subst. Use Misuse 2007, 42:1027-1028.
13. Hakansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur. Addict. Res. 2007, 13:207-215.
14. Moody D.E., Slawson M.H., Strain E.C., Laycock J.D., Spanbauer A.C., Foltz R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 2002, 306:31-39.
15. Gaulier J.M., Marquet P., Lacassie E., Dupuy J.L., Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. J. Forensic Sci. 2000, 45:226-228.
16. Gibson A.E., Degenhardt L.J. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev. 2007, 26:405-410.
17. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 2001, 121:65-69.
18. Kintz P. A new series of 13 buprenorphine-related deaths. Clin. Biochem. 2002, 35:513-516.
19. Pelissier-Alicot A.L., Sastre C., Baillif-Couniou V., Gaulier J.M., Kintz P., Kuhlmann E., Perich P., Bartoli C., Piercecchi-Marti M.D., Leonetti G. Buprenorphine-related deaths: unusual forensic situations. Int. J. Legal Med. 2010, 124:647-651.
20. Pirnay S., Borron S.W., Giudicelli C.P., Tourneau J., Baud F.J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction (Abingdon, England) 2004, 99:978-988.
21. Reynaud M., Petit G., Potard D., Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction (Abingdon, England) 1998, 93:1385-1392.
22. Reynaud M., Tracqui A., Petit G., Potard D., Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am. J. Psychiatry 1998, 155:448-449.
23. Soyka M., Penning R., Wittchen U. Fatal poisoning in methadone and buprenorphine treated patients-are there differences?. Pharmacopsychiatry 2006, 39:85-87.
24. Steentoft A., Teige B., Holmgren P., Vuori E., Kristinsson J., Hansen A.C., Ceder G., Wethe G., Rollmann D. Fatal poisoning in Nordic drug addicts in 2002. Forensic Sci. Int. 2006, 160:148-156.
25. Tracqui A., Kintz P., Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 1998, 22:430-434.
26. Ceccato A., Klinkenberg R., Hubert P., Streel B. Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J. Pharm. Biomed. Anal. 2003, 32:619-631.
27. Lagrange F., Pehourcq F., Baumevieille M., Begaud B. Determination of buprenorphine in plasma by liquid chromatography: application to heroin-dependent subjects. J. Pharm. Biomed. Anal. 1998, 16:1295-1300.
28. Musshoff F., Trafkowski J., Kuepper U., Madea B. An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J. Mass Spectrom. 2006, 41:633-640.
29. Scislowski M., Piekoszewski W., Kamenczak A., Florek E. Simultaneous determination of buprenorphine and norbuprenorphine in serum by high-performance liquid chromatography-electrospray ionization-mass spectrometry. J. Anal. Toxicol. 2005, 29:249-253.
30. Al-Asmari A.I., Anderson R.A. Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2007, 31:394-408.
31. Hoja H., Marquet P., Verneuil B., Lotfi H., Dupuy J.L., Lachatre G. Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 1997, 21:160-165.
32. King R., Bonfiglio R., Fernandez-Metzler C., Miller-Stein C., Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass Spectrom. 2000, 11:942-950.
33. Kronstrand R., Selden T.G., Josefsson M. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 2003, 27:464-470.
34. Moody D.E, Laycock J.D., Spanbauer A.C., Crouch D.J., Foltz R.L., Josephs J.L., Amass L., Bickel W.K. Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 1997, 21:406-414.
35. Hadidi K.A., Oliver J.S. Stability of morphine and buprenorphine in whole blood. Int. J. Legal Med. 1998, 111:165-167.
36. DiFrancesco R., Fischl M.A., Donnelly J., Zingman B.S., McCance-Katz E.F., Moody D.E., Reichman R.C., Gripshover B., Morse G.D. Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. J. Pharm. Biomed. Anal. 2007, 44:188-195.
37. Rodriguez-Rosas M.E., Lofwall M.R., Strain E.C., Siluk D., Wainer I.W. Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 850:538-543.
38. Chiang C.N., Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003, 70:S39-S47.
39. Harris D.S., Mendelson J.E., Lin E.T., Upton R.A., Jones R.T. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin. Pharmacokinet. 2004, 43:329-340.
40. Seldén T., Roman M., Thelander G., Druid H., Kronstrand R. Buprenorphine concentrations in post mortem whole blood and urine from suspected overdose cases 2007, Society of Forensic Toxicologists, Raleigh, NC, USA.